HCV infects at least 185 million people worldwide 1 . HCV infection is often asymptomatic 2, 3 and most of the infected adults can develop chronic infection 4 . More devastating, a significant portion of chronic hepatitis C (CHC) progresses to more severe hepatic pathology, including steatosis, cirrhosis and hepatocellular carcinoma 5 . Besides the escape mutations, impaired and/or insufficient immune response to HCV is believed to account for HCV persistent infection 6 , but the precise mechanisms are still obscure. QPRT catalyzes quinolinic acid (QA), the metabolite of L-Trp in kynurenine (kyn) pathway (KP), to nicotinic acid mononucleotide (NAMN) for de novo synthesis of nicotinamide adenine dinucleotide (NAD), in both prokaryotes and eukaryotes 7, 8 . A tight control of QA level by QPRT is thus required, since hyper QA is often associated with neuropathology and autoimmune diseases 9 . On the other hand, NAD plays important roles in various cellular processes. NAD serves as both a coenzyme for hydride-transfer enzymes and a substrate for an
array of NAD + -dependent enzymes, including Sirtuins, the type III protein lysine deacetylases 10 . Sirtuins, notably SIRT1, primarily involves in inhibition of adipogenesis and enhancement of lipolysis 11 . Unlike other known protein deacetylases, which simply hydrolyze acetyl-lysine residues, the sirtuin-mediated deacetylation reaction couples lysine deacetylation to NAD hydrolysis. This hydrolysis yields O-acetyl-ADP-ribose, the deacetylated substrate and nicotinamide, itself an inhibitor of sirtuin activity. The dependence of sirtuins on NAD links their enzymatic activity directly to the energy status of the cell via the cellular NAD/NADH ratio, the absolute levels of NAD, NADH or nicotinamide or a combination of these variables. HCV replication can decrease the NAD + / NADH ratio by down-regulation of both the expression and enzymatic activity of SIRT1, which converts lipid metabolism to favor HCV replication in hepatocytes 12, 13 . Moreover, NAD is also suggested to play an anti-viral role through PARP superfamily members [14] [15] [16] [17] [18] . However, how HCV affects NAD metabolism has not been fully elucidated.
This work has shown that QPRT is significantly reduced by HCV infection in livers of patients or humanized C/O Tg mice with persistent HCV infection. Mechanistic studies indicate that HCV NS3/4A can drive proteasomal degradation of QPRT facilitated by the E3 ubiquitin ligase Smurf2. Furthermore, overexpressed QPRT can inhibit HCV replication relying on its enzymatic activity. Administration of QPRT agonist or direct NAD treatment can both inhibit HCV replication both in vitro and in vivo. Together, this work has identified that HCV reduces NAD de novo synthesis by promoting QPRT degradation. QPRT thus provides the cytosolic immunity against HCV infection, and QPRT-NAD pathway may serve as a potential target to develop therapeutics against chronic hepatitis C.
Results

QPRT underwent proteasomal degradation by HCV infection.
To determine whether QPRT plays any role in HCV infection, we first measured the expression of QPRT in liver biopsies of CHC patients (Table S1 , 9 of 11 CHC and 6 of 13 cirrhotic patients chosen for serum HCV RNA > 100 IU/mL). Immunohistochemical (IHC) analysis showed in general a much less QPRT expression in CHC and cirrhotic patients (Fig. 1A,B) . A closer inspection of disease progression revealed an inverse correlation between HCV genome copies and hepatic QPRT expression for patients at disease grades G2 and G3, respectively ( Figure S1A ). Too few tissue samples available for G1 grade or massive tissue damage and inflammation at G4 grade prevented a justifiable correlation between HCV replication and QPRT levels. Nevertheless, these results suggested that HCV replication might cause a decrease of QPRT protein levels at the chronic phase (G2 and G3) of hepatitis C.
To better correlate the QPRT levels to HCV infection in vivo, we re-assessed the hepatic QPRT levels in the previously characterized C/O Tg mice 19 , either 2 (acute infection) or 4 weeks (persistent infection) after HCVcc inoculation ( Figure S1B for hepatic HCV RNA copies). Immunoblotting of HCV infected C/O Tg livers indicated that QPRT expression was greatly reduced compared to the mock infection (Fig. 1C) . To delineate how HCV would affect QPRT levels, we further performed in vitro analysis. HCV infection of Huh7.5.1 cells caused a decrease of QPRT protein in a time dependent manner (Fig. 1D) . In this condition, the level of QPRT mRNA remained constant, and even slightly increased at 72 h after HCV infection (Fig. 1E) . Therefore, HCV likely reduced QPRT at the post-translational level. Finally, inhibition of HCV replication in Huh7.1.5 cells by either NS3/4 A protease specific inhibitor VX950 (Fig. 1F) or IFNα (Fig. 1H ) attenuated the declining tendency of QPRT. Thus, QPRT protein level would specifically respond to HCV replication. Both treatments effectively reduced viral replication, as measured by the drastic reduction of NS3 and core (Fig. 1F,H) , and the reduced percentage of GFP + Huh7.5.1 cells (Fig. 1G,I ). In HCVcc J339EM, NS5A was fused with EGFP that was expressed along HCV replication 19 . Of note, the percentage of GFP positive cells was in good linearity to HCV genome copies ( Figure S1C ), we routinely used the percentage of GFP+ cells to represent the replication efficiency of HCV in Huh7.5.1 cells. Finally, less QPRT would lead to a reduced consumption of its enzymatic substrate QA. Mass spectrometric analysis showed that QA concentration in the supernatant was indeed increased by ~9% at 72 h post HCV infection of Huh7.5.1 cells (Fig. 1J) . Therefore, QPRT can be reduced by HCV infection, indicative of its role in regulation of HCV infection. It is thus desirable to delineate the biological significance of QPRT in regulation of HCV replication.
HCV promoted QPRT proteasomal degradation through Smurf2. HCV NS3/4A can direct cleave the type I interferon signaling adaptors, TRIF and MAVS, to evade the innate immune surveillance 20 . To investigate whether a decreased level of QPRT was possibly caused by NS3/4A cleavage, we first performed co-immunoprecipitation (co-IP), which indicated that overexpressed HA-QPRT and Flag-NS3 in HEK293T cells formed a complex (Fig. 2A) . The interaction between QPRT and NS3/4A was further confirmed by far-red fluorescence complementation (BiFC) analysis 21 , where HeLa cells co-expressed with QPRT-iRN97 and iRC98-NS3/4A were specifically lit up (Fig. 2B) . Reciprocal co-IP (Fig. 2C ) and confocal microscopy ( Figure S2A ) analyses further confirmed that the endogenous QPRT interacted with the nascent NS3 and co-localized in the cytoplasm after HCV infection in Huh7.1.5 cells. Therefore, these results indicated that QPRT could make direct protein-protein contact with HCV NS3/4A. Such a close proximity would allow NS3/4A to cleave QPRT. Unexpectedly, however, HA-NS3/4A failed to cleave the co-expressed QPRT in 293T cells (Fig. 2D) , despite of its effective cleavage of VISA/MAVS ( Figure S2B ). Therefore, reduction of QPRT protein levels would not require NS3/4A protease activity. In search for other potential mechanism, we noticed that QPRT ubiquitinylation was evident in response to HCV infection or in the presence of the co-expressed NS3/4A in Huh7.5.1 cells, in a dose dependent manner (Fig. 2E) . Addition of the proteasome inhibitor, MG132, to Huh7.5.1 cells attenuated HCV-induced QPRT degradation (Fig. 2F) and increased the accumulation of ubiquitination of QPRT by the overexpressed FLAG-NS3/4A ( Figure S2C) . A faster decay of QPRT in response to HCV infection after cycloheximide (CHX) inhibition of protein de novo synthesis also indicated that post-translational modification was involved in QPRT down-regulation ( Figure S2D and E) . Therefore, these results suggested that HCV NS3/4A could promote QPRT degradation through the proteasomal pathway. A variety of E3 ubiquitin ligases, Smurf2, Trim25 or HOIP, have been suggested to regulate HCV infection [22] [23] [24] . After each E3 ligase was co-expressed with QPRT in Huh7.5.1 cells, only ectopically expressed Smurf2, but not TRIM25 or HOIP, could enhance QPRT protein degradation in a dose dependent manner (Fig. 2G) . Of note, Smurf2 expression per se was upregulated by HCVcc infection ( Figure S2F ). Moreover, down-regulation of Smurf2 expression by siRNA in Huh7.5.1 ( Figure S2G and S2H for RNAi efficacy) could effectively attenuate the interaction between NS3/4A and QPRT (NS3 panel of co-IP), and reduce HCV-mediated QPRT decay (myc panel of WCL) (Fig. 2H) . Furthermore, co-IP experiment showed that FLAG-Smurf2 could pull down both HA-tagged NS3/4A and myc-tagged QPRT (Fig. 2I) , indicative of formation of a functional tripartite complex. Thus, Smurf2 (E) QPRT mRNA was detected by qRT-PCR and plotted as the ratio to actin. After Huh7.5.1 cells were infected with HCV for 6 h, the increasing concentration of VX950 (F-G) or 1000 U/mL IFNα-2b (H-I) was added for 48 h. Cells were detached and (F,H) detected by immunoblotting for QPRT, NS3 and Core proteins, and (G,I) FACS measured for GFP positivity. (J) Huh7.5.1 cells were infected with HCV J399EM for indicated time, and extracellular QA was analyzed by LC-MS/MS. Full-length gels and blots are included in the Figure S5 . Error bars were SEM of three independent experiments, student t test, *P < 0.05; **P < 0.01, ***P < 0.001. would likely involve in inter-molecular interaction between NS3/4A and QPRT, and promoting QPRT proteasomal degradation by HCV infection. To identify the potential ubiquitin conjugation sites within QPRT, Alanine substitution to K139, K171 and K288 was carried out. Mutant derivatives of QPRT became resistant to proteolysis in the presence of co-expressed Smurf2 in Huh7.5.1 cells (Fig. 2J ). In conclusion, HCV infection likely targeted Smurf2 mediated proteasomal degradation of QPRT.
The enzymatic activity of QPRT was required to suppress HCV replication. To further determine whether QPRT is required to control HCV replication, we downregulated the expression of QPRT by stably expressed shRNA in Huh7.5.1 cells ( Figure S3A for knockdown efficiency). Less QPRT led to a more efficient HCV replication, as indicated by the increased expression of HCV proteins (Fig. 3A) and viral genome replication (Fig. 3B) , compared to the mock treatments. QPRT deficiency also associated with the elevated HCV assembly ( Figure S3B ), budding efficiency ( Figure S3C ), and the specific infectivity ( Figure S3D ). In contrast, Figure S8 . Error bars were SEM of three independent experiments. Student t test, *P < 0.05; **P < 0.01, ***P < 0.01. (Fig. 3C) and the viral replication efficiency (Fig. 3D) , compared to the vector controls. Intracellular ( Figure S3E ) and extracellular ( Figure S3F ) HCV titers were also significantly decreased in QPRT overexpressed cells ( Figure S3E-F) . These results therefore indicated that QPRT was a potential host factor resisting to HCV replication.
The enzymatic active site of QPRT for QA binding 25 consists of three Arginine (R102, R138 and R161) and two Lysine residues (K139 and K171). To investigate whether the catalytic activity of QPRT would involve in inhibition of HCV replication, each of these basic residues was mutagenized and transiently overexpressed in Huh7.5.1 cells. Loss-of-function mutants in general could no longer attenuate HCV replication, with R138Q, K139A and K171A mutation exhibiting the most pronounced effect (Fig. 3E,F) . To substantiate that QPRT relied on its enzymatic activity to suppress HCV replication in cells, HCV replication in Huh7.5.1 cells was further measured in the presence of a QPRT agonist, clofibrate (CLO), or an antagonist, phthalic acid (PHT). To our expectation, CLO (Fig. 3G ) could reduce and PHT (Fig. 3H ) enhance HCV replication, respectively. The inhibitive effect of CLO on HCV replication at least partly relied on QPRT, since down regulation of QPRT made CLO less effective to inhibit HCV replication ( Figure S3G and H) . More significantly, QPRT agonist could inhibit HCV replication in vivo. When CLO was administrated (8 mg, i.p, daily for 2 weeks) in C/O Tg mice two weeks after HCV had established persistent infection, the viral loads in liver (Fig. 3I) and serum (Fig. 3J) were reduced by 2-fold. Therefore, these results suggested that QPRT would involve in cytosolic control of HCV replication, and activation of its catalytic activities might provide a therapeutic benefit against chronic hepatitis C.
QPRT inhibited HCV replication via reduction of cellular lipogenesis.
QPRT is primarily responsible for de novo synthesis of NAD. Indeed, the intracellular NAD concentrations effectively responded to the varying protein levels of QPRT, by either RNAi or overexpression, in Huh7.5.1 cells (Fig. 4A) . Further, addition of cell permeable NAD 26 to Huh7.5.1 cells could inhibit HCV replication in a dose dependent manner (Fig. 4B ). Sirt1 is a NAD + -dependent deacetylase 11 , whose activity and expression are both required to inhibit lipid droplets-dependent HCV replication in hepatocytes 12, 13 . In agreement to these findings, addition of Sirt1 activator Resveratrol (Res) inhibited HCVcc replication in Huh7.5.1 cells (Fig. 4C) , as effectively as that by NAD (Fig. 4B) . Resveratrol can activate Sirt1 to inhibit lipid droplets synthesis, the latter is essential for HCV assembly step as evidenced in Fig. 4C . This was contradictory to a previous report using HCV replicon cells 27 , where the sub-genomic HCV replication does not require the assembly step. Therefore, activation of QPRT or increase of its catabolite NAD would benefit an antiviral effect, potentially through inactivation of cellular lipogenesis.
To substantiate this notion, qPCR analyses showed that NAD or CLO treatment of cells caused a significant decrease of fatty acid synthase (FASN; Fig. 4D,F) and low density lipoprotein receptor (LDLR; Fig. 4E,G) , two lipogenic genes required for efficient HCV replication. The inhibitive potency of NAD or CLO on FASN expression was similar to that by overexpressed QPRT in Huh7.5.1 cells ( Figure S4A ). Consistently, QPRT knockdown in Huh7.5.1 cells caused an increase of FASN ( Figure S4B ) and LDLR ( Figure S4C ) expression. Furthermore, NAD activation of Sirt1 can deacetylate thus destabilize SREBP-1/2, the transcription activators of FASN and LDLR gene expression 28, 29 . In fact, HCV infection or QPRT knockdown in Huh7.5.1 cells could activate SREBP, as indicated by the increase of the nuclear active form of SREBP2 (Fig. 4H-J) . NAD or CLO treatment and overexpression of QPRT, on the other hand, reduced the nuclear translocation of SREBP2 (Fig. 4H,I,K) , indicative of the involvement of QPRT on modulation of Sirt1-SREBP pathway. Therefore, QPRT might inhibit HCV replication through the control of NAD/Sirt1 lipogenesis required for efficient viral replication and infection.
Discussion
The previous reports have shown that IFNγ can up-regulate QPRT in human peripheral blood mononuclear cells 30 , and promote de novo NAD synthesis in murine macrophages cell line 31 , suggesting the potential involvement of QPRT in innate immunity. This work has shown that HCV likely can activate Smurf2-mediated proteasomal degradation of QPRT for a more efficient viral replication. One possible mechanism is that the reduction of QPRT inevitably decelerates de novo NAD synthesis and accelerate the lipogenesis, the latter would favor an efficient HCV replication. Therefore, QPRT may provide a cytosolic immunity against HCV replication through affecting NAD/Sirt1 pathway.
The potential anti-HCV role of NAD has been suggested previously by rather sparse reports 12, 13 , but exactly how NAD regulates HCV replication remains unknown. We show in this work that the reduced NAD/NADH ratio in hepatocytes after HCV infection may be caused by a reduced QPRT catabolism. We have further provided evidence, both in vitro and in vivo, that modulation of enzymatic activities of QPRT, by its activator or inhibitor, can effectively modulate HCV replication efficiency. In consequence, intracellular NAD would reflect both the amount and activity of QPRT, and execute its potential anti-HCV activity through Sirt1. We show in this study that increased NAD or activation of QPRT by CLO both can inactivate SREBP2 and downregulate expression of FASN and LDLR, two essential lipogenic genes required for HCV infection.
In sum, we tentatively conclude that QPRT involve in cytosolic immunity against HCV replication through insurance of an unfavorable NAD/Sirt1 lipogenesis. Reduced QPRT activity, thus impaired QPRT immunity occurred in chronic hepatitis C, can be reconstituted by QPRT agonist. This also point to a potential therapeutic target for hepatitis C. Of course, one needs to develop better QPRT agonists than CLO in this respect. This is not only because the relatively lower potency of CLO in reduction of HCV titers, but also because CLO, a lipid lowering drug, can reduce serum cholesterol and converts LDL to HDL. Higher serum cholesterol and LDL levels have been suggested to increase the probability of a sustained viral response (SVR) by IFN based therapy in chronic hepatitis C 32 . The situation in using CLO is further complicated that CLO is also a PPARα activator, and long-term treatment of HCV core-transgenic mice with CLO may induce hepatocarcinogenesis 33 . Despite of all these complications associated with CLO, this work shed a light onto development of a more specific and potent QPRT enzymatic activator, that may help stockpile more arsenals in the endeavor of HCV cure in the future.
Materials and Methods
Animals and Patients. The humanized mice (C/O
Tg ) permissive for HCV were used for HCV infection, exactly as previously described 19 . In brief, C/O Tg (n = 5, male, 8-12 weeks of age) were tail vein inoculated with HCV J399EM (TCID 50 = 1 × 10 8 /mL) or mock saline. Mice were randomly withdrawn at the indicated time points and sacrificed for analyses of viral loads and QPRT expression. Human liver tissues were collected using biopsy needles guided by ultrasound scan or during a laparoscopy. Tissues were divided into three groups, health volunteer (HV), chronic hepatitis C (CHC) and cirrhosis with chronic HCV infection, and four groups with disease grade (G1, G2, G3 and G4) of hepatitis patients as previously described 34 (Table S1 ). Figure S9 . Error bars were SEM of three independent experiments. Student t test, *P < 0.05; **P < 0.01, ***P < 0.01.
Reagents and
Scientific RepoRts | 7: 5876 | DOI:10.1038/s41598-017-06254-4 V900386), Phthalic acid (PHT, Sigma, 80010), Clofibrate (Sigma, C6643) and cycloheximide (Sigma, C7698) were purchased from where indicated. The HCV infectious clone J399EM and the measurement of 50% tissue culture infective dose (TCID 50 ) have been described previously 36 . Virus titers in cell lysates and supernatants were detected for TCID50 by endpoint dilution assays (EPDA) as previously described 37 . MOI = 0.1 was routinely applied to infect Huh7.5.1 cells (courtesy of Dr. Jin Zhong, Institute Pasteur of Shanghai, CAS). Cells were routinely cultured in DMEM (Invitrogen) supplemented with 2 mM L-glutamine, 2 mM nonessential amino acids, 100 mM HEPES and 10% FBS (Invitrogen, 10099-141). Huh7.5.1 cells stably expressing QPRT shRNA were selected and maintained in the presence of 2 μg/mL Puromycin (Sigma, P8833), and those stably expressing Flag-QPRT with 800 μg/mL G418 (Millipore, 345810).
Flow cytometry.
To quantify the kinetics of viral replication, Huh7.5.1 cells infected with HCV J399EM for the indicated time, trypsinized and fixed in 4% paraformaldehyde before subject to flow cytometric analysis in FACSAria III (BD Biosciences, CA). GFP channel excited at 488 nm was acquired and analyzed using FlowJo7.6.1 software (Ashland, OR).
Confocal microscopy. BiFC was used to assess protein-protein interaction as previously reported 21 . In brief, HeLa cells (2 × 10 5 ) were transfected with pcDNA3.1-NS3/4A-iRC98 and pCDNA3.1-QPRT-iRN97 (a total of 1 μg) for 48 h. After paraformaldehyde fixation, cells were incubated in 1 µg/mL Hoechst3342 (DNA stain) for 1 min before mounting. Red fluorescence from the iRFP channel (λ ex = 640 nm), and the nuclei counterstained with Hoechst 33342 (λ ex = 405 nm) were captured using a UltraView VOX confocal system (Perkin Elmer), and analyzed with Volocity software (Perkin Elmer).
Quantitative PCR. Total RNA was extracted from liver (0.1 g), cells (1 × 10 6 ), sera (0.1 mL), or cell culture medium (250 μL) using Trizol or Trizol LS reagent (Invitrogen). qPCR reactions were performed as described previously 38 in an StepOne Plus (ABI, CA), using iTaq ™ Universal SYBR ® Green Supermix (Bio-Rad). Primers for indicated genes were listed in Table S2 . HCV RNA copy numbers in liver tissues, sera, cell lysates and culture media were measured as previously described 19 . Data were analyzed with ABI software version 2.0.3 (Applied Biosystems).
Immunoprecipitation and Immunoblotting. Experiments were performed as described previously 39 . In brief, 293T cells (5 × 10 5 ) were transfected with indicated expression plasmids (2 μg) by jetPRIME reagents (114-07, Polyplus S.A.) for 24 h. Cell lysates (400 μL) were immunoprecipitated by indicated antibody (1 μg) using Prorein G Dynabeads (Life Technology). Protein complexes were further resolved in SDS-PAGE, and detected by immunoblotting with the primary antibodies where indicated. Chemiluminescent HRP Substrate (Millipore) was used to detect indicated bands.
Immunohistochemistry. IHC staining of various patient liver tissues was performed as previously described 19 , except that the rabbit monoclonal antibody against QPRT (1:200, Abcam) was used as the primary antibody. Images were acquired by Digital Pathology system (Pannoramic MIDI, Hungary) and analyzed with Pannoramic Viewer software (3dHISTECH, Hungary).
Measurement of intracellular NAD and quinolinic acid. After cells (2 × 10
5 ) where indicated were washed with cold PBS three times, sample preparation and intracellular NAD measurement were carried out as described in specification of NAD/NADH Quantification Colorimetric Kit (BioVision). The sample preparation 40 for LC-MS analysis 41 of quinolinic acid (QA) was performed as previously described. Briefly, 10 μM deuterium D3 quinolinic acid (QA-d3, J&K Scientific Ltd) was spiked to the culture supernatants as the internal standard. Proteins in supernatants were precipitated by trichloracetic acid (Sigma, 3% final concentration), the supernatant was then filtered through a spin column (MW cutoff = 3 kDa, Millipore Amicon) at 14,000 × g at 4 °C for 10 min. The filtrates were 10 × diluted and injected (5 µL) to a Acquity H-Class UPLC system (Waters, HSS T3 2.1 × 100 mm, 1.8 µm particle column. Solution A, 0.3% formic acid in water, and solution B, 0.3% methanol in water). The analytes were eluted (0.3 mL/min flow rate) by the following gradients: 0-1.7 min (95%A and 5%B), 5.0-6.0 min (50% A and 50%B) and 6.5-9.0 min (95%A-95%B). The triple quadrupole in the + ve ESI mode was used in a Quattro Premier XE mass spectrometer (Waters, MA). Standard solutions of QA for calibration curves were prepared from stock solutions. The final concentrations of unknowns were calculated by interpolation of the standard curves.
Protein turnover assay. The half life of QPRT protein was assessed by cycloheximide (CHX) chase assay as described previously 42, 43 . In brief, Huh7.5.1 cells were infected with HCVcc for 48 h, 300 μg/mL CHX was then added to inhibit de novo protein synthesis. At the indicated time, cells lysates were prepared for immunoblotting of QPRT and HCV NS3. After linear regression of QPRT levels, the half life of QPRT was calculated from the slope of the best fit line.
Statistical analysis. Data were analyzed using unpaired two-tailed student's t-test with GraphPad Prism 6 software (San Diego, CA). P values < 0.05 were considered statistically significant.
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